Form 4: Adaptive Biotechnologies Corp: Chief Scientific Officer Harlan S Robins Reports Stock Transactions

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, reports acquisition and disposal of common stock to cover tax obligations related to RSU vesting.

Summary

• On March 4, 2025, Harlan S Robins acquired 355,000 shares of Adaptive Biotechnologies Corp common stock at $0.
• Following this acquisition, Robins directly held 1,376,180 shares.
• On March 5, 2025, Robins sold 40,603 shares at $6.98 and 56,053 shares at $6.99 to cover tax withholding obligations related to the vesting of RSUs.
• After these sales, Robins directly held 1,279,524 shares.
• These transactions were not discretionary trades but were mandated by the issuer's election under the equity incentive plans to cover tax obligations.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions related to RSU vesting, which is neither particularly positive nor negative.

Management Comments

• The sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's holdings and potential alignment with shareholder interests.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but this is likely offset by the fact that the sales are non-discretionary and related to tax obligations.

Key Dates